These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18421452)

  • 41. Pharmacogenetic association between
    Khan S; Mandal RK; Elasbali AM; Dar SA; Jawed A; Wahid M; Mahto H; Lohani M; Mishra BN; Akhter N; Rabaan AA; Haque S
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30509962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population.
    Yadav D; Kumar R; Dixit RK; Kant S; Verma A; Srivastava K; Singh SK; Singh S
    Cureus; 2019 Apr; 11(4):e4425. PubMed ID: 31245212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
    Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
    Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison between acetylator phenotype and genotype polymorphism of n-acetyltransferase-2 in tuberculosis patients.
    Rana SV; Ola RP; Sharma SK; Arora SK; Sinha SK; Pandhi P; Singh K
    Hepatol Int; 2012 Jan; 6(1):397-402. PubMed ID: 22020825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study on Genotyping Polymorphism and Sequencing of N-Acetyltransferase 2 (NAT2) among Al-Ahsa Population.
    Zahra MA; Kandeel M; Aldossary SA; Al-Taher A
    Biomed Res Int; 2020; 2020():8765347. PubMed ID: 32626768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS.
    Araújo-Mariz C; Lopes EP; Acioli-Santos B; Maruza M; Montarroyos UR; Ximenes RA; Lacerda HR; Miranda-Filho Dde B; Albuquerque Mde F
    PLoS One; 2016; 11(6):e0157725. PubMed ID: 27332812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients.
    Perwitasari DA; Irham LM; Darmawan E; Mulyani UA; Atthobari J
    Indian J Tuberc; 2016 Jul; 63(3):139-143. PubMed ID: 27865233
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Richardson M; Kirkham J; Dwan K; Sloan DJ; Davies G; Jorgensen AL
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):293-305. PubMed ID: 30871660
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis.
    Sheng YJ; Wu G; He HY; Chen W; Zou YS; Li Q; Zhong L; Huang YM; Deng CL
    Infect Genet Evol; 2014 Jun; 24():34-40. PubMed ID: 24607341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity.
    Shimizu Y; Dobashi K; Mita Y; Endou K; Moriya S; Osano K; Koike Y; Higuchi S; Yabe S; Utsugi M; Ishizuka T; Hisada T; Nakazawa T; Mori M
    Tuberculosis (Edinb); 2006 Sep; 86(5):374-81. PubMed ID: 16246623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
    Shi J; Xie M; Wang J; Xu Y; Liu X
    Pharmacogenomics; 2015 Dec; 16(18):2083-97. PubMed ID: 26616266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil.
    Ridolfi F; Amorim G; Peetluk LS; Haas DW; Staats C; Araújo-Pereira M; Cordeiro-Santos M; Kritski AL; Figueiredo MC; Andrade BB; Rolla VC; Sterling TR;
    J Infect Dis; 2024 Mar; 229(3):813-823. PubMed ID: 38262629
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Mohamed Noor NF; Salleh MZ; Mohd Zim MA; Bakar ZA; Fakhruzzaman Noorizhab MN; Zakaria NI; Lailanor MI; Teh LK
    Pharmacogenomics; 2022 Jun; 23(9):531-541. PubMed ID: 35615896
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.
    Surarak T; Chumnumwat S; Nosoongnoen W; Tragulpiankit P
    Clin Transl Sci; 2024 Apr; 17(4):e13795. PubMed ID: 38629592
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.
    Yamada S; Tang M; Richardson K; Halaschek-Wiener J; Chan M; Cook VJ; Fitzgerald JM; Elwood RK; Brooks-Wilson A; Marra F
    Pharmacogenomics; 2009 Sep; 10(9):1433-45. PubMed ID: 19761367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic polymorphisms of N-acetyltransferase 2 & susceptibility to antituberculosis drug-induced hepatotoxicity.
    Sharma SK; Jha BK; Sharma A; Sreenivas V; Upadhyay V; Jaisinghani C; Singla R; Mishra HK; Soneja M
    Indian J Med Res; 2016 Dec; 144(6):924-928. PubMed ID: 28474630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
    Chan SL; Chua APG; Aminkeng F; Chee CBE; Jin S; Loh M; Gan SH; Wang YT; Brunham LR
    PLoS One; 2017; 12(10):e0186200. PubMed ID: 29036176
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
    Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
    Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients.
    Igumnova V; Capligina V; Krams A; Cirule A; Elferts D; Pole I; Jansone I; Bandere D; Ranka R
    J Infect Chemother; 2016 Jul; 22(7):472-7. PubMed ID: 27236516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
    Yuliwulandari R; Susilowati RW; Wicaksono BD; Viyati K; Prayuni K; Razari I; Kristin E; Syafrizal ; Subagyo ; Sri Diana E; Setiawati S; Ariyani A; Mahasirimongkol S; Yanai H; Mushiroda T; Tokunaga K
    J Hum Genet; 2016 Jun; 61(6):533-7. PubMed ID: 26911349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.